Search Results
Your search for all items matches 3067 pages
Showing 1 - 50
Melissa Johnson, MD, on Advanced Nonsquamous NSCLC: Second-Line Risvutatug Rezetecan and Adebrelimab
Melissa Johnson, MD, of Sarah Cannon Research Institute, reviews results from a cohort of the phase I ARTEMIS-101 trial, which she was the discussant of at AACR 2026. The subgroup of cohort 1a included patients with advanced nonsquamous non–small cell lung cancer and no actionable genomic...
Case 3: Newly Diagnosed Advanced Uterine Papillary Serous Carcinoma
This is Part 3 of Navigating the Immunotherapy Landscape in Advanced/Recurrent Endometrial Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Krishnansu Tewari, Noelle Cloven, and Alyssa Bujnak discuss the management of...
Case 2: Newly Diagnosed Advanced MMRp Endometrioid Adenocarcinoma
This is Part 2 of Navigating the Immunotherapy Landscape in Advanced/Recurrent Endometrial Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Krishnansu Tewari, Noelle Cloven, and Alyssa Bujnak discuss the management of...
Case 1: Advanced and Recurrent MMRd Endometrioid Adenocarcinoma of the Uterus
This is Part 1 of Navigating the Immunotherapy Landscape in Advanced/Recurrent Endometrial Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Krishnansu Tewari, Noelle Cloven, and Alyssa Bujnak discuss the management of...
Yuji Shibata, MD, PhD, on HER2-Mutant NSCLC: Mechanisms of Zongertinib Resistance
Yuji Shibata, MD, PhD, of The University of Texas MD Anderson Cancer Center, describes findings on the identification of novel HER2 mutations that mediate resistance to the tyrosine kinase inhibitor zongertinib among patients with non–small cell lung cancer (NSCLC); these data also indicated that...
Lyudmila A. Bazhenova, MD, on ROS1-Positive NSCLC: Taletrectinib in TKI-Naive Patients
Lyudmila A. Bazhenova, MD, of the University of California, San Diego, presents updated data from the phase II TRUST-I and TRUST-II trials. With approximately 3 years of follow-up in the pooled analysis, investigators now conclude that the next-generation, selective ROS1 tyrosine kinase inhibitor...
Fabrice Barlesi, MD, PhD, on Resectable NSCLC: IPH5201 Plus Durvalumab and Platinum-Based Chemotherapy
Fabrice Barlesi, MD, PhD, of Gustave Roussy, discusses interim results from the phase II MATISSE trial, which looked at dual CD39 and PD-L1 inhibition in patients with resectable non–small cell lung cancer (NSCLC). The study investigated the combination of IPH5201, an investigational anti-CD39...
Manale El Kharbili, PhD, on a Novel Strategy to Eliminate MRD in HER2-Mutant NSCLC
Manale El Kharbili, PhD, of the University of Colorado Anschutz Medical Campus, discusses preclinical work that showed HER2-mutant non–small cell lung cancer (NSCLC) cell lines retained demonstrated dynamic changes in cell surface protein expression in treatment-naive vs zongertinib-induced...
Jonathan Riess, MD, on Zoldonrasib in Previously Treated Patients With KRAS G12D–Mutant NSCLC
Jonathan Riess, MD, of the University of California, Davis, describes preliminary data on the safety and clinical activity of zoldonrasib (also known as RMC-9805), an oral, RAS(ON) G12D–selective, tricomplex inhibitor, in previously treated patients with KRAS G12D–mutant non–small cell lung cancer...
Thi Van Trinh Tran, PhD, on the Histopathology of Lung Cancer in Neversmokers
Thi Van Trinh Tran, PhD, of the National Cancer Institute, describes histologic and prognostic findings from the largest cohort of lung cancer in people who have never smoked. Tumor-infiltrating lymphocyte data also reflected refined risk stratification (Abstract 1302).
Case 3: Distal Esophageal HER2-Positive Adenocarcinoma
This is Part 3 of From Diagnosis to Durability: Elevating Outcomes in Gastroesophageal Adenocarcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Yelena Janjigian, Daniela Molena, and Steven Maron discuss the nonoperative...
Case 2: Oligometastatic Gastric Adenocarcinoma
This is Part 2 of From Diagnosis to Durability: Elevating Outcomes in Gastroesophageal Adenocarcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Yelena Janjigian, Daniela Molena, and Steven Maron discuss the management...
Case 1: Locally Advanced GEJ Adenocarcinoma
This is Part 1 of From Diagnosis to Durability: Elevating Outcomes in Gastroesophageal Adenocarcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Yelena Janjigian, Daniela Molena, and Steven Maron discuss the perioperative ...
Case 3: Metastatic RCC With Symptomatic Progression After IO/IO
This is Part 3 of Optimizing Patient Selection and Outcomes in Post-IO Advanced RCC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Hans Hammers, Michael Harrison, and Qian Qin discuss the treatment of metastatic renal cell...
Case 2: Advanced RCC With Mild Disease Progression After IO/IO
This is Part 2 of Optimizing Patient Selection and Outcomes in Post-IO Advanced RCC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Hans Hammers, Michael Harrison, and Qian Qin discuss the treatment of advanced renal cell...
Case 1: RCC With Disease Progression After Adjuvant Pembrolizumab
This is Part 1 of Optimizing Patient Selection and Outcomes in Post-IO Advanced RCC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Hans Hammers, Michael Harrison, and Qian Qin discuss the treatment of renal cell carcinoma...
Kent Shih, MD, on Use of GEP for SLNB and Follow-up Planning in Melanoma
Kent Shih, MD, of Tennessee Oncology, shares three patient cases that illustrate how gene-expression profiling (GEP) in patients with melanoma helps shape the decision to proceed to sentinel lymph node biopsy (SLNB) and how often and thorough follow-up should be with medical oncology.
Kent Shih, MD, on Adjuvant Therapy in Melanoma: How Does GEP Testing Factor In?
Kent Shih, MD, of Tennessee Oncology, presents three patients cases that show how the use of gene-expression profile testing guides patient and practitioner decision-making when choosing the appropriate path of adjuvant treatment among individuals with melanoma.
Neha Vapiwala, MD, on Highlights in Prostate Cancer From ASCO GU 2026
Neha Vapiwala, MD, of the University of Pennsylvania, discusses key themes in prostate cancer data presented at this year’s symposium, including personalization of therapy, treatment sequencing considerations, the role of radiopharmaceuticals, long-term radiotherapy results, using AI and associated ...
Maha H.A. Hussain, MD, FASCO, FACP, on Metastatic Castration-Resistant Prostate Cancer: BRCAAway Trial in Patients With DNA Repair Defects
Maha H.A. Hussain, MD, FASCO, FACP, of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, reviews results from the BRCAAway trial, which evaluated the efficacy of abiraterone vs olaparib vs the two agents in combination as first-line therapy for patients with metastatic...
Case 3: Perioperative Management of Resectable EGFR-Mutant NSCLC
This is Part 3 of Optimizing the Care Continuum for EGFR-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Suresh Ramalingam, Zofia Piotrowska, and Helena Yu discuss the perioperative management of resectable...
Case 2: Acquired Resistance After First-Line Osimertinib-Based Therapy in EGFR L858R–Mutant NSCLC
This is Part 2 of Optimizing the Care Continuum for EGFR-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Suresh Ramalingam, Zofia Piotrowska, and Helena Yu discuss the management of acquired resistance after...
Case 1: First-Line Therapy for EGFR-Mutant Metastatic NSCLC
This is Part 1 of Optimizing the Care Continuum for EGFR-Mutant NSCLC, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Suresh Ramalingam, Zofia Piotrowska, and Helena Yu discuss the first-line treatment of EGFR-mutant non–small ...
Matthew D. Galsky, MD, FASCO, on Muscle-Invasive Bladder Cancer: Enfortumab Vedotin and Pembrolizumab
Matthew D. Galsky, MD, FASCO, of Mount Sinai Tisch Cancer Center, discusses findings from the randomized phase III KEYNOTE-B15/EV-304 study, which is evaluating neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab followed by radical cystectomy plus pelvic lymph node dissection vs...
Thomas Powles, MD, PhD, FCRP, on a Novel Antibody-Drug Conjugate in Previously Treated Advanced Urothelial Cancer
Thomas Powles, MD, PhD, FCRP, of Barts Cancer Centre, Queen Mary University of London, shares findings from the phase II RC48G001 trial of disitamab vedotin, an antibody-drug conjugate comprising a novel anti-HER2 antibody, disitamab, and an MMAE payload. The agent demonstrated “promising antitumor ...
Amar Kishan, MD, on Recurrent Prostate Cancer: Hormone Therapy and Postoperative Radiotherapy
Amar Kishan, MD, University of California, Los Angeles, discusses results from an individual patient data meta-analysis of randomized trials to quantify the benefit of adding hormone therapy to postoperative radiotherapy in patients with localized prostate cancer after radical prostatectomy...
Enrique Gallardo, MD, on mCRPC: Enzalutamide With or Without Radium-223
Enrique Gallardo, MD, of Parc Taulí University Hospital, presents final overall survival results from the EORTC 1333/PEACE-3 trial, which is a phase III trial evaluating the addition of radium-223 to enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone...
Anna Clare Wilkins, PhD, MRCP, MBBChir, on Localized Prostate Cancer: MMAI-Derived Biomarker
Anna Clare Wilkins, PhD, MRCP, MBBChir, of The Institute of Cancer Research, discusses the external validation of a digital pathology-based multimodal artificial intelligence (MMAI)-derived prognostic biomarker using data from the phase III CHHiP trial. CHHiP evaluated conventional vs...
Scott Tyldesley, MD, FRCPC, on Localized Prostate Cancer: External Beam vs Brachytherapy Boost RT
Scott Tyldesley, MD, FRCPC, of BC Cancer Vancouver, reports on the 15-year survival analysis from the ASCENDE-RT trial, which randomly assigned patients to receive either prostate brachytherapy or the external-beam radiotherapy boost; both arms also received androgen-deprivation therapy....
Joseph A. Sparano, MD, on Multimodal AI Models for Predicting Breast Cancer Recurrence
Joseph A. Sparano, MD, of the Icahn School of Medicine at Mount Sinai, discusses the performance of experimental multimodal artificial intelligence (AI) models integrating clinical, molecular, and histopathologic features to provide prognostic information for early and late recurrence using primary ...
Jame Abraham, MD, FACP, on HER2-Positive Metastatic Breast Cancer: Choosing a Regimen in Clinical Practice
Jame Abraham, MD, FACP, puts findings from several trials in HER2-positive breast cancer into context, including HER2CLIMB, which investigated tucatinib, trastuzumab, and capecitabine in pretreated patients with metastatic disease; DESTINY Breast-09, which evaluated fam-trastuzumab deruxtecan-nki...
Case 3: Management of Multiply Relapsed DLBCL
This is Part 3 of Personalizing Treatment Pathways in Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jeremy Abramson, J. Erika Haydu, and Jacob Soumerai discuss the treatment of multiply relapsed...
Case 2: Second-Line Management of Relapsed DLBCL
This is Part 2 of Personalizing Treatment Pathways in Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jeremy Abramson, J. Erika Haydu, and Jacob Soumerai discuss the second-line treatment of relapsed ...
Case 1: Management of Early Relapsed DLBCL
This is Part 1 of Personalizing Treatment Pathways in Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jeremy Abramson, J. Erika Haydu, and Jacob Soumerai discuss the treatment of early relapsed...
Jame Abraham, MD, FACP, on T-DXd in HER2-Positive Early Breast Cancer: Follow-up Data
Jame Abraham, MD, FACP, discusses follow-up data from the DESTINY Breast-05 and DESTINY Breast-11 trials of fam-trastuzumab deruxtecan-nki (T-DXd) for HER2-positive early breast cancer. DESTINY Breast-05 examined the agent given postneoadjuvantly, while DESTINY Breast-11 evaluated the agent in a...
Jame Abraham, MD, FACP, on a Novel Oral SERD for ER-Positive, HER2-Negative Early Breast Cancer
Jame Abraham, MD, FACP, discusses the global, randomized lidERA Breast Cancer trial. Results from lidERA position giredestrant as a potential new standard of care for patients with estrogen receptor (ER)-positive, HER2-negative stage I to III early breast cancer, marking the first phase III trial...
Marcel Verheij, MD, PhD, on Resectable Gastric Cancer: Comparing Three Preoperative Regimens
Marcel Verheij, MD, PhD, of Radboud University Medical Center, presents findings from the phase II CRITICS-II trial, which compared three preoperative regimens while omitting adjuvant treatment among patients with nonmetastatic resectable gastric cancer: chemotherapy, chemotherapy followed by...
Case 3: Metastatic HR-Positive/HER2-Negative Breast Cancer With PTEN Loss and Emergent ESR1 Mutation
This is Part 3 of Balancing Benefit and Burden: Managing Toxicities in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Neil Iyengar, Sara Tolaney, and William Gradishar...
Case 2: De Novo Metastatic PIK3CA-Altered HR-Positive/HER2-Negative Breast Cancer and Non–Insulin-Dependent Diabetes
This is Part 2 of Balancing Benefit and Burden: Managing Toxicities in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Neil Iyengar, Sara Tolaney, and William Gradishar...
Case 1: PIK3CA-Altered HR-Positive/HER2-Negative Metastatic Breast Cancer
This is Part 1 of Balancing Benefit and Burden: Managing Toxicities in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Neil Iyengar, Sara Tolaney, and William Gradishar...
Stephen Lam Chan, MD, FRCP, MRCP, on HCC: Pembrolizumab After Resection or Local Ablation
Stephen Lam Chan, MD, FRCP, MRCP, of the Hong Kong Cancer Institute, The Chinese University of Hong Kong, discusses findings from the phase III KEYNOTE-937 trial, which evaluated the efficacy and safety of pembrolizumab vs placebo as adjuvant therapy in patients with hepatocellular carcinoma (HCC)...
Matthew Strickland, MD, on Locally Advanced Gastric/GEJ Cancer: Tislelizumab Plus Chemoradiotherapy
Matthew Strickland, MD, of Massachusetts General Hospital, reviews results from the phase IIb TERRIFIC trial, which compared the efficacy and safety of the PD-1 inhibitor tislelizumab plus chemoradiotherapy vs chemoradiotherapy or chemotherapy alone in the neoadjuvant treatment of patients with...
Dina Ioffe, MD, on Disparities in HCC: Do They Affect Systemic Care?
Dina Ioffe, MD, of Fox Chase Cancer Center, describes the results of an analysis that sought to determine how race/ethnicity, insurance status, and socioeconomic status may affect patterns of systemic treatment for metastatic hepatocellular carcinoma (HCC) (Abstract 489).
Daniela Molena, MD, on Surgical Journey in the MATTERHORN Trial
Daniela Molena, MD, of Memorial Sloan Kettering Cancer Center, discusses a comparison of the surgical journeys of patients with resectable gastric/gastroesophageal adenocarcinoma who either received fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab or FLOT plus placebo in...
Elena Elimova, MD, on HER2-Positive Gastroesophageal Cancer: Zanidatamab Plus Chemotherapy
Elena Elimova, MD, of Princess Margaret Cancer Centre, presents findings from the primary analysis of the phase III HERIZON-GEA-01 trial, which evaluated zanidatamab, a dual HER2-targeted bispecific antibody, plus chemotherapy with or without the PD-1 inhibitor tislelizumab vs trastuzumab plus...
Elizabeth Smyth, MD, on FLOT Administration in the MATTERHORN Trial
Elizabeth Smyth, MD, of the Oxford NIHR Biomedical Research Centre, Churchill Hospital, presents findings from an analysis of the MATTERHORN trial, a phase III study that examined fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) plus durvalumab in patients with resectable...
Samuel J. Klempner, MD, on Advanced Gastric/GEJ Cancer: Zolbetuximab Plus mFOLFOX6 and Nivolumab
Samuel J. Klempner, MD, of Massachusetts General Hospital, discusses results from the phase II ILUSTRO trial, which evaluated the combination of the anti-CLDN18.2 antibody zolbetuximab plus mFOLFOX6 and nivolumab in patients with CLDN18.2-positive; HER2-negative; locally advanced, unresectable, or...
Ghassan K. Abou-Alfa, MD, on Tremelimumab Rechallenge in Unresectable HCC: Safety Outcomes
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, outlines an assessment of baseline characteristics and safety outcomes in HIMALAYA trial participants who were rechallenged with tremelimumab after being treated with the STRIDE regimen (single dose of tremelimumab plus...
Ghassan K. Abou-Alfa, MD, on a Novel First-Line Regimen for Unresectable HCC Under Study
Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center, reviews the goals of the upcoming phase III ARTEMIDE-HCC01 trial, which will examine the efficacy and safety of rilvegostomig (a novel bispecific anti–PD-1/anti-TIGIT antibody) plus bevacizumab with or without tremelimumab as...
Mikkael Sekeres, MD, MS, on MDS and Exposure to Agent Orange
Mikkael Sekeres, MD, MS, Chief, Division of Hematology and Professor of Medicine at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, presents findings from a new study that connects exposure to the herbicide Agent Orange to earlier and more severe...
